01977oam 2200457Ia 450 991069895460332120090820090806.0(CKB)5470000002398329(OCoLC)421097512(EXLCZ)99547000000239832920090702d2008 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] postmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemicRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Office of Counterterrorism and Emerging Threats :Center for Drug Evaluation and Research :Center for Biologics Evaluation and Research :Center for Devices and Radiological Health :Center for Food Safety and Applied Nutrition,[2008]1 online resource (12 pages)"Draft guidance"."Procedural"."December 2008".Guidance for industry DrugsSide effectsReportingGovernment policyUnited StatesDietary supplementsGovernment policyUnited StatesInfluenzaDrugsSide effectsReportingGovernment policyDietary supplementsGovernment policyInfluenza.United States.Food and Drug Administration.Office of Counterterrorism and Emerging Threats.Center for Drug Evaluation and Research (U.S.)Center for Biologics Evaluation and Research (U.S.)Center for Devices and Radiological Health (U.S.)Center for Food Safety and Applied Nutrition (U.S.)GPOGPOGPOBOOK9910698954603321Guidance for industry3434577UNINA